Landon Chan

So thrilled to see our collaborative publication with @tedradonc, @ma5RN and many others now online in @JCO_ASCO These data from a large, multinational cohort provide further support for EBRT's role in the management of HCC. ascopubs.org/doi/10.1200/JC…

@NiuSanford @OncoAlert The optimal dose and fractionation for HCC still confuses to me. Sometimes it is hard to get the dose high with a 5 fraction regimen (eg 40Gy/5) due to OAR but a higher BED can be achieved with a 10 fraction regimen (eg 52.5Gy/10). In that case should we go for 10 fraction…?

Another study showing HCC radiosensitive. In a VA cohort (67% BCLC C, heavily pre-tx), local control similar bw 50Gy in 10 v 5 fx after adjusting for tx vol. Despite larger tumors, 10fx achieved 82% 2yr LC, a pragmatic fallback regimen if constraints preclude fewer fx.@OncoAlert

📢New from EORTC-ESTRO OligoCare in @TheLancetOncol: this 3rd #OligoCare consensus paper recommends preferred primary endpoints for trials of metastasis directed therapies in #oligometastatic cancer, supporting more patient centred & comparable research. 👉bit.ly/3QCihGD

@mollylisc and I are looking forward to hosting Conversations In Thoracic Oncology 2026 (#CITO26) 🫁 at @CUHK_MC in 2+ weeks' time in #HongKong! Welcoming speakers who are #RisingStars 🌟 in #ThoracicOncology from #HongKong 🇭🇰, #Japan 🇯🇵, #Taiwan 🇹🇼, #ChineseMainland 🇨🇳, #Singapore 🇸🇬 and #SouthKorea 🇰🇷. @stephanieplsaw @DrYujiUehara @TonyMok9 amongst many others! @apoddc @APCLC_2023 #drugdevelopment @IASLC

Clinical guideline for the diagnosis and treatment of fibrolamellar carcinoma @HEP_Journal doi.org/10.1097/HEP.00… 👏Timely guideline 👉still very difficult to treat tumor @ASCO @myESMO @EASLnews @ILCAnews

Happy to share this interactive contouring tutorial for dose-escalated RT in locally advanced pancreas ca, which follows our NRG consensus contouring atlas. Thank you @johnroubil, @dsouzl, @aiims2738, & the @eContourRadOnc team for working on this case! econtour.org/cases/180

Link to contouring atlas: redjournal.org/article/S0360-…

Like PROSPECT, the RT arm in CONVERT received less chemo. Not only was planned # of cycles less (6 v 8), but ~25% never received ANY multiagent chemo. Hence trial compensates for RT omission by delivering more chemo. In that light, similar DFS/OS (even w N2) actually remarkable.

Happy to share our review article on Recent advancements for RT in HCC is now online in ESMO Gastrointestinal Oncology!😃 Emerging indications for RT include bridging to transplant, combining with systemic therapy, and its use in oligo-met/PD cases! sciencedirect.com/science/articl…

@OscarTahuahua Thank you for highlighting our article!

Recent advancements in radiotherapy for hepatocellular carcinoma For years, RT played only a limited role in HCC management. Today, SBRT can achieve >90% 2 year local control with RILD <5% (Radiation-Induced Liver Disease) Proton therapy reports ~88% 3-year local control with low hepatic toxicity. Not universally adopted, but difficult to ignore with modern data. esmogastro.org/article/S2949-… @OncoAlert

🫁 Catching up on #ASCO25 news? ⭐ Don't miss this insightful interview with @mollylisc on the LC-SHIELD study, which is evaluating AI-based lung cancer screening in people who have never smoked but are at a high risk for lung cancer. ➡️ Watch: buff.ly/PvgD9rw #lcsm

Checkpoint inhibitors are now standard in advanced HCC, but resistance is common. This review explores how TACE, radiation, and novel combos (triplets, bispecifics, vaccines) may expand efficacy and indications. Read here: journals.sagepub.com/doi/epdf/10.11…

We are thrilled to have our new #Dean of @CUHKMedicine @pwychiu visit our small (but very productive! 🤗) Department of #ClinicalOncology @CUHKofficial to discuss future strategic directions and plans. @TonyMok9 #AnthonyChan #WinnieYeo #BrigetteMa #StephenChan @mollylisc @LandonLChan #KelvinYan

@changhoon_yoo @StephenLChan1 Learning from the giants 🙏🏻🙏🏻🙏🏻 more work to come 🙂

@LandonLChan @StephenLChan1 Whole team efforts. Congrats to us 😀

Happy to share our team’s work published on JHep! This is the first prospective trial testing cabozantinib in the post-IO setting for HCC. Hope this will provide a new standard and benchmark for future trials! @StephenLChan1 @changhoon_yoo Dr CJ Kyung journal-of-hepatology.eu/article/S0168-…

Congratulations @CUHKofficial Landon Chan, and thank you to all colleagues from Zhongshan Shanghai @NUSingapore Zhongshan Xiamen for joining the quarterly @MSKCancerCenter @MSK_DeptOfMed East West #Liver #HCC Rounds

@GABOUALFA @CUHKofficial @NUSingapore @MSKCancerCenter @MSK_DeptOfMed @EileenMOReilly @HardingJJMD @Layalmahmasani Thank you for the opportunity and participation in this excellent discussion @GABOUALFA!

Great experience and amazing interaction between participant’s & faculties from👉 🇵🇭🇧🇩🇮🇳🇭🇰🇹🇼🇻🇳🇳🇵🇮🇩🇵🇰🇺🇿🇲🇾🇲🇲🇯🇵🇲🇳 & 🇹🇼 🇩🇪🇯🇵🇸🇬🇬🇧 (🇪🇸🇨🇦+/- 🇦🇷) Take Home Message 👌 multidisciplinar approach is key 👉 The 🧰 of the #BCLC2022 reflects the Tumor Board Decision 🔝New era #IO & #LRT

Heading✈️home from Singapore Many🙏 to ESMO to organize this great advanced course on HCC 👏Excellent lecturers & speakers 👍great discussions with esteemed colleagues from all over ASIA 👉Lots of opportunities but also many inequalities and challenges in access to effective medicines in HCC @myESMO